Exchange: OTC·Updated 07:30 PM EST

GMXAY News

News
all
press releases
The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.
Stocktwits
Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.
Stocktwits

Advertisement|Remove ads.